Cancer in Pregnancy: Therapeutic Decisions at the Intersection of Two Lives
Authors:
- Antônio BragaABAntônio Braga
- Jorge de Rezende-FilhoJRJorge de Rezende-Filho
- Maurício MagalhãesMMMaurício Magalhães
- Sue Yazaki SunSSSue Yazaki Sun
- Andreia Cristina de MeloAMAndreia Cristina de Melo
- Gustavo Yano CalladoGCGustavo Yano Callado
- Fernanda da Costa NegraesFNFernanda da Costa Negraes
- Maria Vitória Moura FajardoMFMaria Vitória Moura Fajardo
- Susana Cristina Aidé Viviani FialhoSFSusana Cristina Aidé Viviani Fialho
- Edward Araujo JúniorEdward Araujo Júnior
- Glória CalagnaGlória Calagna
Open Access
- 2 April 2026
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 16 (7) , 1070
Abstract
Background: Cancer during pregnancy is a rare but increasingly encountered condition due to delayed childbearing and improved survival of women with cancer. The coexistence of malignancy and pregnancy poses complex diagnostic and therapeutic challenges, requiring careful balance between maternal prognosis and fetal safety. Objective: This review aims to summarize current evidence on the diagnosis and multidisciplinary management of cancer during pregnancy, focusing on the safe use of oncologic therapies, obstetric decision-making, and maternal and fetal outcomes. Methods: A narrative review was conducted based on literature identified in PubMed/MEDLINE, Scopus, and Web of Science from January 2000 to September 2025. Search terms included pregnancy-associated cancer, oncologic treatment during pregnancy, obstetric management, and fetal outcomes. Relevant clinical guidelines, registry data, and reference lists were also reviewed. Results: Breast cancer, cervical cancer, melanoma, hematologic malignancies, and gestational trophoblastic neoplasia represent the most frequently reported cancers during pregnancy. Evidence indicates that selected cancer treatments can be administered safely without compromising maternal prognosis. Chemotherapy after the first trimester is generally associated with acceptable fetal outcomes. Physiological changes in pregnancy may delay diagnosis and influence drug pharmacokinetics. Radiotherapy, targeted therapies, and immunotherapies remain limited because of potential fetal toxicity. Avoiding iatrogenic prematurity is a central principle of obstetric management. Conclusions: Cancer during pregnancy should no longer be considered an absolute therapeutic dilemma. With individualized multidisciplinary care, effective maternal treatment and favorable fetal outcomes are increasingly achievable.Keywords
This publication has 63 references indexed in Scilit:
- Cancer in pregnancy: FIGO Best practice advice and narrative reviewInternational Journal of Gynecology & Obstetrics, 2025
- BCR::ABL1 Tyrosine Kinase Inhibitors During Pregnancy, a Disproportionality Analysis of VigibaseClinical Pharmacology & Therapeutics, 2025
- Choriocarcinoma in neonates and infants: A severe but curable diseasePediatric Blood & Cancer, 2024
- Bridging the divide: unveiling mutual immunological pathways of cancer and pregnancyInflammation Research, 2024
- Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and NewbornsJAMA Network Open, 2023
- Malignancy in pregnancy: Multimodality imaging and treatmentCancer, 2023
- Cancer in pregnancy: overview and epidemiologyAbdominal Radiology, 2022
- Risk of malformation after ondansetron in pregnancy: An updated systematic review and meta‐analysisBirth Defects Research, 2020
- Association of Maternal First-Trimester Ondansetron Use With Cardiac Malformations and Oral Clefts in OffspringJAMA, 2018
- The psychological impact of a cancer diagnosed during pregnancy: determinants of long‐term distressPsycho-Oncology, 2011